In the PIONEER AF-PCI trial, 2124 patients with nonvalvular AF undergoing PCI were randomized 1:1:1 to dual therapy comprising of reduced dose 15 mg rivaroxaban with a P2Y12 inhibitor for 12 months, very low dose rivaroxaban 2.5 mg b.i.d. plus DAPT for 1, 6, or 12 months or triple therapy with VKA [20]. The gene discussed is P2RY12; the disease is atrial fibrillation.